Avicenna Alliance: enhanced knowledge, improved decisions, better outcomes
FULL MENU

Ensuring the Quality of in silico Evidence for Medical Devices: A Risk-Based Framework for Global Regulatory Acceptance

Ensuring the Quality of in silico Evidence for Medical Devices: A Risk-Based Framework for Global Regulatory Acceptance

BACK

Ensuring the Quality of in silico Evidence for Medical Devices: A Risk-Based Framework for Global Regulatory Acceptance

The use of in silico methods—computational modelling and simulation—to support the development, evaluation, and regulatory approval of medical devices is expanding rapidly. These approaches offer clear benefits in accelerating innovation, reducing development burden, and strengthening safety assessment, yet their regulatory acceptance remains inconsistent across jurisdictions. This variability reflects differences in model maturity, documentation practices, and the absence of globally harmonised criteria for assessing credibility. Building on established standards and regulatory guidance, this position paper outlines a risk-informed framework for the credible generation, assessment, and regulatory utilisation of in silico evidence that could be implemented across the medical device lifecycle. The framework emphasises clear definition of a question of interest and context of use, proportional credibility requirements based on model risk, and rigorous application of verification, validation, and uncertainty quantification. Emerging challenges posed by data-driven and hybrid models, including artificial intelligence, highlighting additional governance and data integrity considerations are also addressed. Importantly, the generation of in silico evidence increasingly relies on bioinformatics and computational biomedicine workflows, including the integration of heterogeneous biomedical data sources (e.g. medical imaging, real-world data, and population-level datasets), preprocessing and feature extraction pipelines, and hybrid mechanistic–data-driven modelling approaches. In this perspective, the authors argue that the credibility of in silico evidence is not determined solely at the level of the executable model, but across the full computational pipeline, encompassing data provenance, preprocessing, model implementation, and reproducible analysis workflows.


DOWNLOAD YOUR COPY HERE

IMAGE GALLERY:

NEWS

News ADVANCING THE VIRTUAL HUMAN TWIN ECOSYSTEM - Avicenna Alliance at VHT Net Initiative Meeting

ADVANCING THE VIRTUAL HUMAN TWIN ECOSYSTEM - Avicenna Alliance at VHT Net Initiative Meeting

On 20 October, Avicenna Alliance was represented by many members and partners, including our President and Secretary General, Thierry Marchal, at the annual VHT Net initiative meeting, organised by the VPH - The Society for In Silico Medicine at the European Commission.

News SILICA General Assembly - Strengthening collaboration on AI, synthetic data and in silico methods in healthcare

SILICA General Assembly - Strengthening collaboration on AI, synthetic data and in silico methods in healthcare

The Avicenna Alliance is pleased to support initiatives that bring stakeholders together to advance the use of artificial intelligence, synthetic data, and computational modelling and simulation in healthcare.

News Avicenna Days (AAD) 2027

Avicenna Days (AAD) 2027

Three days. One journey. From research to real-world impact.

Sign up for our monthly newsletter!

Sign up for our monthly newsletter!

Fill in the fields you find below

Avicenna Alliance is an initiative of:

Avicenna VPH

© 2018-2026 Avicenna Alliance | powered by We Berry